Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

335 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical benefit in patients with metastatic bone disease: results of a phase 3 study of denosumab versus zoledronic acid.
Vadhan-Raj S, von Moos R, Fallowfield LJ, Patrick DL, Goldwasser F, Cleeland CS, Henry DH, Novello S, Hungria V, Qian Y, Feng A, Yeh H, Chung K. Vadhan-Raj S, et al. Among authors: goldwasser f. Ann Oncol. 2012 Dec;23(12):3045-3051. doi: 10.1093/annonc/mds175. Epub 2012 Jul 31. Ann Oncol. 2012. PMID: 22851406 Free article. Clinical Trial.
Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, Scagliotti GV, Sleeboom H, Spencer A, Vadhan-Raj S, von Moos R, Willenbacher W, Woll PJ, Wang J, Jiang Q, Jun S, Dansey R, Yeh H. Henry DH, et al. Among authors: goldwasser f. J Clin Oncol. 2011 Mar 20;29(9):1125-32. doi: 10.1200/JCO.2010.31.3304. Epub 2011 Feb 22. J Clin Oncol. 2011. PMID: 21343556 Clinical Trial.
Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial.
Durand JP, Deplanque G, Montheil V, Gornet JM, Scotte F, Mir O, Cessot A, Coriat R, Raymond E, Mitry E, Herait P, Yataghene Y, Goldwasser F. Durand JP, et al. Among authors: goldwasser f. Ann Oncol. 2012 Jan;23(1):200-205. doi: 10.1093/annonc/mdr045. Epub 2011 Mar 22. Ann Oncol. 2012. PMID: 21427067 Free article. Clinical Trial.
Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and/or targeted therapy: the VACANCE study.
Rousseau B, Loulergue P, Mir O, Krivine A, Kotti S, Viel E, Simon T, de Gramont A, Goldwasser F, Launay O, Tournigand C. Rousseau B, et al. Among authors: goldwasser f. Ann Oncol. 2012 Feb;23(2):450-7. doi: 10.1093/annonc/mdr141. Epub 2011 May 16. Ann Oncol. 2012. PMID: 21576285 Free article. Clinical Trial.
Use of chemotherapy near the end of life: what factors matter?
Rochigneux P, Raoul JL, Beaussant Y, Aubry R, Goldwasser F, Tournigand C, Morin L. Rochigneux P, et al. Among authors: goldwasser f. Ann Oncol. 2017 Apr 1;28(4):809-817. doi: 10.1093/annonc/mdw654. Ann Oncol. 2017. PMID: 27993817 Free article.
Reply to Bone morphogenetic proteins and zoledronic acid.
Bertagna X, Boudou-Rouquette P, Alexandre J, Soubrane O, Goldwasser F. Bertagna X, et al. Among authors: goldwasser f. Ann Oncol. 2009 Dec;20(12):2019. doi: 10.1093/annonc/mdp503. Epub 2019 Dec 4. Ann Oncol. 2009. PMID: 32560025 Free article. No abstract available.
335 results